These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33196188)

  • 1. Assessing hERG1 Blockade from Bayesian Machine-Learning-Optimized Site Identification by Ligand Competitive Saturation Simulations.
    Mousaei M; Kudaibergenova M; MacKerell AD; Noskov S
    J Chem Inf Model; 2020 Dec; 60(12):6489-6501. PubMed ID: 33196188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure driven design of novel human ether-a-go-go-related-gene channel (hERG1) activators.
    Guo J; Durdagi S; Changalov M; Perissinotti LL; Hargreaves JM; Back TG; Noskov SY; Duff HJ
    PLoS One; 2014; 9(9):e105553. PubMed ID: 25191697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization and Evaluation of Site-Identification by Ligand Competitive Saturation (SILCS) as a Tool for Target-Based Ligand Optimization.
    Ustach VD; Lakkaraju SK; Jo S; Yu W; Jiang W; MacKerell AD
    J Chem Inf Model; 2019 Jun; 59(6):3018-3035. PubMed ID: 31034213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. hERG Blockade Prediction by Combining Site Identification by Ligand Competitive Saturation and Physicochemical Properties.
    Goel H; Yu W; MacKerell AD
    Chemistry (Basel); 2022 Sep; 4(3):630-646. PubMed ID: 36712295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First universal pharmacophore model for hERG1 K
    Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY
    J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach.
    Raman EP; Yu W; Lakkaraju SK; MacKerell AD
    J Chem Inf Model; 2013 Dec; 53(12):3384-98. PubMed ID: 24245913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling using site-identification by ligand competitive saturation (SILCS) with multiple probe molecules.
    Yu W; Lakkaraju SK; Raman EP; Fang L; MacKerell AD
    J Chem Inf Model; 2015 Feb; 55(2):407-20. PubMed ID: 25622696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).
    MacKerell AD; Jo S; Lakkaraju SK; Lind C; Yu W
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129519. PubMed ID: 31911242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring protein-protein interactions using the site-identification by ligand competitive saturation methodology.
    Yu W; Jo S; Lakkaraju SK; Weber DJ; MacKerell AD
    Proteins; 2019 Apr; 87(4):289-301. PubMed ID: 30582220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.
    Durdagi S; Randall T; Duff HJ; Chamberlin A; Noskov SY
    BMC Pharmacol Toxicol; 2014 Mar; 15():14. PubMed ID: 24606761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pore-Lipid Interface: Role of Amino-Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain.
    Perissinotti L; Guo J; Kudaibergenova M; Lees-Miller J; Ol'khovich M; Sharapova A; Perlovich GL; Muruve DA; Gerull B; Noskov SY; Duff HJ
    Mol Pharmacol; 2019 Aug; 96(2):259-271. PubMed ID: 31182542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Site-Identification by Ligand Competitive Saturation (SILCS) assisted pharmacophore modeling.
    Yu W; Lakkaraju SK; Raman EP; MacKerell AD
    J Comput Aided Mol Des; 2014 May; 28(5):491-507. PubMed ID: 24610239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric Coupling Between Drug Binding and the Aromatic Cassette in the Pore Domain of the hERG1 Channel: Implications for a State-Dependent Blockade.
    Kudaibergenova M; Guo J; Khan HM; Zahid F; Lees-Miller J; Noskov SY; Duff HJ
    Front Pharmacol; 2020; 11():914. PubMed ID: 32694995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site Identification by Ligand Competitive Saturation (SILCS) simulations for fragment-based drug design.
    Faller CE; Raman EP; MacKerell AD; Guvench O
    Methods Mol Biol; 2015; 1289():75-87. PubMed ID: 25709034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Physics- and Machine-Learning-Based Method to Identify Druggable Binding Sites Using SILCS-Hotspots.
    Nordquist EB; Zhao M; Kumar A; MacKerell AD
    J Chem Inf Model; 2024 Oct; 64(19):7743-7757. PubMed ID: 39283165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reproducing crystal binding modes of ligand functional groups using Site-Identification by Ligand Competitive Saturation (SILCS) simulations.
    Raman EP; Yu W; Guvench O; Mackerell AD
    J Chem Inf Model; 2011 Apr; 51(4):877-96. PubMed ID: 21456594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational fragment-based binding site identification by ligand competitive saturation.
    Guvench O; MacKerell AD
    PLoS Comput Biol; 2009 Jul; 5(7):e1000435. PubMed ID: 19593374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation.
    Yu W; Weber DJ; MacKerell AD
    J Chem Theory Comput; 2023 May; 19(10):3007-3021. PubMed ID: 37115781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs.
    Durdagi S; Subbotina J; Lees-Miller J; Guo J; Duff HJ; Noskov SY
    Curr Med Chem; 2010; 17(30):3514-32. PubMed ID: 20738248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.